Corvus Pharmaceuticals (CRVS)Perceptive Advisors LLC added to its stake +375K shares

2.67M

Shares reported · +375K vs prior quarter

0.60%

Disclosed portfolio weight

$39.9M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On July 21, 2026, Ian T. Clark delivered notice of his intention to resign from the board of directors (the “Board”) of Corvus Pharmaceuticals, Inc. (the “Company”), effective as of July 22, 2026.”
2. Aug 6, 2026Company filing · Form 8-K · ResultsReported its results

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Corvus Pharmaceuticals

For Corvus Pharmaceuticals, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its CRVS page.

How this filing works

• SEC Form 13F

Other disclosures at Corvus Pharmaceuticals

• SEC Form 13F-HRMay 29, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRAug 14, 2025
• SEC Form 4Jul 2, 2025
• SEC Form 4Jul 2, 2025

Everything OQRO holds on this company is on its CRVS page.